QTRXQuanterix Corporation
The Read
Quanterix’s stock has historically dropped sharply—up to about 20%—after earnings due to revenue misses, wider losses, cash burn worries, and key executive departures despite some positive collaborations and leadership changes.
The schedule
- Thu15Oct
Potential strategic partnership update regarding clinical rollout for CNS diagnostic assays.
- Wed20Jan
Strategic roadmap presentation for the next-generation Simoa platform and in vitro diagnostics commercialization.
- Sun14Feb
Full-year 2026 financial results, final formal 2027 guidance, and operating margin outlook.
- Mon15Feb
Q3 results featuring preliminary 2027 revenue guidance and clinical service margin updates.
- Wed5May
Q1 2027 earnings report evaluating first-quarter execution against the full-year roadmap.
Past
- Tue15Sep
High probability of a secondary equity offering or convertible debt issuance to extend the financial runway into 2027.
- Thu13Aug
Actual outcome: Bear
Quanterix reported Q2 revenue of $32.9 million, missing its own guidance by 9%, and lowered its full-year outlook due to broad-based market softness and commercial execution challenges. Although EPS was in-line with estimates at -$0.37, the top-line miss and reduced guidance drove the stock down to the bear floor. The company's efforts to reshape its sales strategy and appoint a new Chief Commercial Officer were not enough to offset concerns over continued pressure in academic and biopharma markets.
Scheduled Q2 2026 earnings with heavy focus on cash runway and top-line stabilization.
- Mon27Jul
Actual outcome: Bear · $3.48 at outcome
Quanterix shares fell 5.2% following the Alzheimer's Association International Conference, approaching the $3.35 bear floor and continuing to slide to $2.79 by mid-August. The absence of a major positive catalyst or breakthrough biomarker data from the event failed to generate investor enthusiasm, leaving the market cautious ahead of the company's upcoming Q2 earnings report.
Key data presentation and industry adoption commentary at the Alzheimer's Association International Conference (AAIC).
- Wed6May
Actual outcome: Bear · $2.64 at outcome
Quanterix reported a Q1 revenue miss and wider-than-expected losses, raising concerns about its cash burn and ability to sustain growth. The stock's 19.8% decline was further exacerbated by the unexpected announcement of CFO Vandana Sriram's departure shortly after the earnings release, which overshadowed a new Alzheimer's biomarker collaboration with Tempus.
Q1 2026 results and commentary on CNS and pharma services demand will signal whether QTRX can sustain high-20s revenue growth while narrowing losses; clean execution and firm orders could lift the stock toward $3.90, while renewed cash burn concerns or weak guidance could push it back toward $3.90.
- Fri1May
Actual outcome: Bear · $2.69 at outcome
Quanterix reported a wider-than-expected Q1 loss of $0.39 per share compared to the consensus estimate of a $0.31 loss, and also missed revenue expectations. Despite announcing a collaboration with Tempus to integrate blood-based Alzheimer's biomarker testing, the top- and bottom-line misses drove a 20.9% decline in the stock price by the outcome date.
Potential follow-on equity raise around $3.30 to extend cash runway; if framed as strategic growth capital it could stabilize QTRX near $3.80, but at current depressed levels there is meaningful risk of a dilution-driven air pocket toward $3.80.
- Mon2Mar
Actual outcome: Bear · $3.82 at outcome
While Quanterix met EPS estimates at -$0.49, the stock fell sharply as 2026 revenue guidance and cash burn projections likely failed to reassure investors facing uncertainty from new healthcare policies. The 19.1% decline through the outcome date and subsequent slide to $3.30 indicates that the market prioritized concerns over the company's long-term fiscal health and regulatory headwinds over the inline quarterly results.
Reporting full-year 2025 results with a focus on cash burn and revenue guidance for the new fiscal year under the Trump administration's healthcare policies.
